EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Engineering a Trispecific EGFR × c-MET × VEGF Antibody with Multiple Mechanisms of Action for Antitumor Activity in Gastrointestinal Cancer Models

Hao Jiang, Ying Jin, Yuqiang Xu, Peng Chen, Simin Wu, Zhengxia Zha, Meixia Fu, Guangmao Mu, Bin Ma, Ping Sun, Sheng Huang, Fulai Zhou und 3 weitere

Antibodies · 29.10.2026 · 15 (6) · 100

DOI: 10.3390/antib15060100 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Antibodies, online erschienen am 29.10.2026. Verfasst von Hao Jiang und 14 weiteren Autor:innen. Die Arbeit nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

A leading cause of cancer-related mortality worldwide, gastrointestinal (GI) cancers are often recalcitrant to single agent therapies. Dysregulations of the EGFR, cMET, and VEGF pathways are frequently observed together in these malignancies, making simultaneous multi-targeted therapy a promising strategy.

Objectives

TAVO412, a trispecific antibody against EGFR, cMET, and VEGFA, employed complementary mechanisms of action to inhibit multiple GI cancer cell lines. Methods/Results: TAVO412 effectively suppressed phosphorylation of the targeted receptors, thereby inhibiting cancer cell proliferation in vitro. The antibody, engineered with enhanced Fc function, displayed strong antibody-dependent cytotoxicity, antibody-dependent cellular phagocytosis, and complement-dependent cytotoxicity. In vivo studies demonstrated that the anti-VEGFA domain design was central to drug efficacy, with the non-cleavable linker format performing optimally, presumably due to tumor-localized VEGF binding. In a pancreatic cancer model, antitumor activity was primarily driven by anti-VEGF and anti-EGFR activities. Moreover, TAVO412 demonstrated superior antitumor activity compared to bevacizumab or amivantamab monotherapy, and was as effective as their combination in colorectal and esophageal cancer models.

Conclusions

Collectively, these preclinical findings laid the groundwork for clinical trials of TAVO412 in patients with advanced gastrointestinal cancers expressing EGFR, cMET, and VEGF.

Zitieren

APA

Jiang, H., Jin, Y., Xu, Y., Chen, P., Wu, S., Zha, Z., Fu, M., Mu, G., Ma, B., Sun, P., Huang, S., Zhou, F., Han, C., MacWilliams, M. P., & Chiu, M. L. (2026). Engineering a Trispecific EGFR × c-MET × VEGF Antibody with Multiple Mechanisms of Action for Antitumor Activity in Gastrointestinal Cancer Models. Antibodies, 15(6), 100. https://doi.org/10.3390/antib15060100

Vancouver

Jiang H, Jin Y, Xu Y, Chen P, Wu S, Zha Z, et al. Engineering a Trispecific EGFR × c-MET × VEGF Antibody with Multiple Mechanisms of Action for Antitumor Activity in Gastrointestinal Cancer Models. Antibodies. 2026;15(6):100. doi:10.3390/antib15060100

BibTeX
@article{Jiang2026,
  author = {Jiang, Hao and Jin, Ying and Xu, Yuqiang and Chen, Peng and Wu, Simin and Zha, Zhengxia and Fu, Meixia and Mu, Guangmao and Ma, Bin and Sun, Ping and Huang, Sheng and Zhou, Fulai and Han, Chao and MacWilliams, Maria P. and Chiu, Mark L.},
  title = {Engineering a Trispecific EGFR × c-MET × VEGF Antibody with Multiple Mechanisms of Action for Antitumor Activity in Gastrointestinal Cancer Models},
  journal = {Antibodies},
  year = {2026},
  volume = {15},
  number = {6},
  pages = {100},
  doi = {10.3390/antib15060100}
}
Kostenlos starten →